Literature DB >> 25698479

Prognostication in the era of a new stressor for myocardial perfusion imaging.

Wanda Acampa1, Marco Salvatore2, Alberto Cuocolo3.   

Abstract

Mesh：

Year:  2015        PMID： 25698479     DOI： 10.1007/s12350-015-0075-x

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN： 1071-3581            Impact factor:   5.952


× No keyword cloud information.
  26 in total

Review 1.  Prognostic value of gated myocardial perfusion SPECT.

Authors:  Leslee J Shaw; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2004 Mar-Apr       Impact factor: 5.952

2.  Comparison of the myocardial blood flow response to regadenoson and dipyridamole: a quantitative analysis in patients referred for clinical 82Rb myocardial perfusion PET.

Authors:  Behnaz Goudarzi; Kenji Fukushima; Paco Bravo; Jennifer Merrill; Frank M Bengel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-06-09       Impact factor: 9.236

3.  Prediction of myocardial infarction versus cardiac death by gated myocardial perfusion SPECT: risk stratification by the amount of stress-induced ischemia and the poststress ejection fraction.

Authors:  T Sharir; G Germano; X Kang; H C Lewin; R Miranda; I Cohen; R D Agafitei; J D Friedman; D S Berman
Journal:  J Nucl Med       Date:  2001-06       Impact factor: 10.057

4.  A blunted heart rate response to regadenoson is an independent prognostic indicator in patients undergoing myocardial perfusion imaging.

Authors:  Fadi G Hage; Phillip Dean; Fahad Iqbal; Jaekyeong Heo; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2011-07-22       Impact factor: 5.952

5.  The prognostic value of regadenoson myocardial perfusion imaging.

Authors:  Fadi G Hage; Gopal Ghimire; Davis Lester; Joshua Mckay; Steven Bleich; Stephanie El-Hajj; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2015-02-14       Impact factor: 5.952

6.  Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results.

Authors:  Manuel D Cerqueira; Patricia Nguyen; Peter Staehr; S Richard Underwood; Ami E Iskandrian
Journal:  JACC Cardiovasc Imaging       Date:  2008-05

Review 7.  Regadenoson: a new myocardial stress agent.

Authors:  Wael Al Jaroudi; Ami E Iskandrian
Journal:  J Am Coll Cardiol       Date:  2009-09-22       Impact factor: 24.094

8.  Myocardial kinetics of Tc-MIBI in canine myocardium after dipyridamole.

Authors:  D K Glover; R D Okada
Journal:  Circulation       Date:  1990-02       Impact factor: 29.690

9.  Regadenoson provides perfusion results comparable to adenosine in heterogeneous patient populations: a quantitative analysis from the ADVANCE MPI trials.

Authors:  John J Mahmarian; Leif E Peterson; Jiaqiong Xu; Manuel D Cerqueira; Ami E Iskandrian; Timothy M Bateman; Gregory S Thomas; Faisal Nabi
Journal:  J Nucl Cardiol       Date:  2014-10-07       Impact factor: 5.952

10.  Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy.

Authors:  Leslee J Shaw; Daniel S Berman; David J Maron; G B John Mancini; Sean W Hayes; Pamela M Hartigan; William S Weintraub; Robert A O'Rourke; Marcin Dada; John A Spertus; Bernard R Chaitman; John Friedman; Piotr Slomka; Gary V Heller; Guido Germano; Gilbert Gosselin; Peter Berger; William J Kostuk; Ronald G Schwartz; Merill Knudtson; Emir Veledar; Eric R Bates; Benjamin McCallister; Koon K Teo; William E Boden
Journal:  Circulation       Date:  2008-02-11       Impact factor: 29.690
View more
  2 in total

1.  Review of Cardiovascular Imaging in the Journal of Nuclear Cardiology in 2015-Part 2 of 2: Myocardial perfusion imaging.

Authors:  Fadi G Hage; Wael A AlJaroudi
Journal:  J Nucl Cardiol       Date:  2016-02-18       Impact factor: 5.952

2.  Comparison of the prognostic value of regadenoson and adenosine myocardial perfusion imaging.

Authors:  Afshin Farzaneh-Far; Linda K Shaw; Allison Dunning; Jorge D Oldan; Christopher M O'Connor; Salvador Borges-Neto
Journal:  J Nucl Cardiol       Date:  2015-05-19       Impact factor: 5.952
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.